Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.56 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | EBP | Q15125 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GUSB | P08236 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5852136 | 0.73 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL4249763 | 0.73 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL21035309 | 0.73 | — | — | |
| SCHEMBL19779489 | 0.73 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL23866553 | 0.71 | PIK3CD (0.35) | — | |
| SCHEMBL21024538 | 0.71 | GNAO1 (0.71) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL595977 | 0.71 | GNAO1 (0.92) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL19275197 | 0.71 | GNAO1 (0.71) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL25963757 | 0.71 | GNAO1 (0.71) | GNAO1GNAI3GNAI1SPHK1KCNH2 | |
| SCHEMBL11204905 | 0.71 | GNAO1 (0.51) | GNAO1GNAI3GNAI1S1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | GNAO1 3151/4885GNAI3 1504/4885GNAI1 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.